Search for: "ASTRAZENECA LP" Results 101 - 120 of 161
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
1 Jun 2011, 11:22 am
Ct. 365, 374 (2008); see also AstraZeneca LP v. [read post]
23 Feb 2012, 6:22 am by Asher Bearman
In contrast, corporate VC operations are built on a variety of structures, some of which are quite simple, and some of which resemble the traditional GP/LP structure, but many of which are novel and innovative. [read post]
10 Sep 2012, 7:28 pm by FDABlog HPM
In July, after a court battle with FDA that started around mid-March when AstraZeneca Pharmaceuticals LP (“AstraZeneca”) sought to enjoin FDA from granting final ANDA approvals for generic SEROQUEL following FDA’s denial (without comment) of two citizen petitions AstraZeneca submitted to FDA last year concerning labeling carve-out issues, the U.S. [read post]
28 Jul 2010, 12:06 am by Kelly
(Patent Docs) Crestor (Rosuvastatin) – US: Patent infringement complaint following amended ANDA filing: AstraZeneca Pharmaceuticals LP et al. v. [read post]
29 Jun 2010, 6:01 pm by Duncan
(Docket Report) US: Update on reverse settlement agreements – Amici curiae brief filed with US Court of Appeals: In re Ciprofloxacin Hydrochloride Antitrust Litigation (IP Whiteboard) (PatLit) US: An uneven debate on ‘takings’ in pharmaceutical patent law (Patent Docs) Products Aldara (Imiquimod) – US: Graceway’s injunction and Nycomed’s dismissal denied in Aldara suit (Patent Docs) Argatroban – US: Patent for Argatroban found valid, injunction… [read post]
Astrazeneca Pharmaceutical LP held a leave of absence or a leave extension can constitute a reasonable accommodation under the ADA “in some circumstances”, although in that case ultimately concluded the plaintiff could not show her request for twelve additional months of leave was facially reasonable. [read post]
16 Jan 2009, 5:00 am
(IP finance) US: Medarex, Eurand and Alexion file actions against Director Dudas seeking revised patent term adjustment determinations (Patent Docs) US: Kubin panel questions motivation behind reversal in new Written Description Training Materials (Patent Docs) US: The obviousness of DNA - Federal Circuit heard oral argument for In re Kubin last week (Patent Docs)   Products Antara (Fenofibrate) – US: Oscient and Ethypharm file patent infringement suit against Lupin over Antara… [read post]
16 Apr 2012, 1:29 am by FDABlog HPM
District Court are Motions for Summary Judgment filed by FDA and AstraZeneca Pharmaceuticals LP (here and here) concerning FDA’s approval of ANDAs for generic versions of SEROQUEL (quetiapine fumarate) Tablets and the Agency’s decision, discussed in a March 27, 2012 Letter Decision, concerning the scope and applicability of 3-year marketing exclusivity in that case. [read post]
Astrazeneca Pharmaceutical LP held a leave of absence or a leave extension can constitute a reasonable accommodation under the ADA “in some circumstances”, although in that case ultimately concluded the plaintiff could not show her request for twelve additional months of leave was facially reasonable. [read post]
30 Jun 2010, 5:52 am
(Docket Report) US: Update on reverse settlement agreements – Amici curiae brief filed with US Court of Appeals: In re Ciprofloxacin Hydrochloride Antitrust Litigation (IP Whiteboard) (PatLit) US: An uneven debate on ‘takings’ in pharmaceutical patent law (Patent Docs)   Products Aldara (Imiquimod) – US: Graceway’s injunction and Nycomed’s dismissal denied in Aldara suit (Patent Docs) Argatroban – US: Patent for Argatroban found valid, injunction issued… [read post]
23 Jul 2009, 3:15 am
Astrazeneca Pharmaceuticals LP), because of Bexis' firm's involvement in the litigation (although not this aspect). [read post]
26 Jan 2011, 1:31 am by Ben Vernia
In April of last year, we obtained a $520 million settlement with AstraZeneca LP and AstraZeneca Pharmaceuticals LP to resolve allegations that marketing of the anti-psychotic drug Seroquel for uses not approved as safe and effective by the FDA caused false claims to be submitted to federal health care programs. [read post]
8 Apr 2015, 3:41 pm by Sean Wajert
AstraZeneca Pharm., LP, 634 F.3d 1352, 1362 (11th Cir. 2011) (“Several considerations shape the physician’s medical judgment, including both individual patient concerns and drug-specific information regarding the propriety of a drug’s use for treatment of a patient’s given condition . . . [read post]